2 results
Approved WMOCompleted
First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measured by change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotide modifies…
Approved WMOWill not start
The study primary objective will consist of assessing the safety and tolerability of single IV (bolus + infusion) doses of glenzocimab in patients with an acute ischemic stroke administered on top of the best emergency standard of care (including…